References
- American Cancer Society. Cancer Facts & Figures 2014. Atlanta: American Cancer Society, 2014
- Davis KL, Mitra D, Kotapati S, et al. Direct economic burden of high-risk and metastatic melanoma in the elderly: evidence from the SEER-Medicare linked database. Appl Health Econ Health Policy 2009;7:31-41
- Pollack LA, Li J, Berkowitz Z, et al. Melanoma survival in the United States, 1992 to 2005. J Am Acad Dermatol 2011;65(5 Suppl 1):S78-86
- Bhatia S, Tykodi SS, Thompson JA. Treatment of metastatic melanoma: an overview. Oncology 2009;23:488-96
- Finn L, Markovic SN, Joseph RW. Therapy for metastatic melanoma: the past, present, and future. BMC Med 2012;10:23
- Yervoy prescribing information. Available at: http://packageinserts.bms.com/pi/pi_yervoy.pdf [Last accessed 18 May 2014]
- Zelboraf prescribing information. Available at: http://www.gene.com/download/pdf/zelboraf_prescribing.pdf [Last accessed 18 May 2014]
- Dean E, Lorigan P. Advances in the management of melanoma: targeted therapy, immunotherapy and future directions. Expert Rev Anticancer Ther 2012;12:1437-48
- Hodi FS, O’Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010;363:711-23
- Robert C, Thomas L, Bondarenko I, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 2011;364:2517-26
- Vultur A, Villanueva J, Herlyn M. Targeting BRAF in advanced melanoma: a first step toward manageable disease. Clin Cancer Res 2011;17:1658-63
- Chapman PB, Hauschild A, Robert C, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011;364:2507-16
- Chapman PB, Hauschild A, Robert C, et al. Updated overall survival (OS) results for BRIM-3, a phase III randomized, open-label, multicenter trial comparing BRAF inhibitor vemurafenib (vem) with dacarbazine (DTIC) in previously untreated patients with BRAF V600E mutated melanoma. (2012 ASCO Meeting abstract.) J Clin Oncol 2012;30(15 Suppl):8502
- Hauschild A, Grob JJ, Demidov LV, et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicenter, open-label, phase 3 randomised controlled trial. Lancet 2012;380:358-65
- Flaherty KT, Robert C, Hersey P, et al. Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med 2012;367:107-14
- Guy GP Jr, Ekwueme DU, Tangka FK, Richardson LC. Melanoma treatment costs: a systematic review of the literature, 1990–2011. Am J Prev Med 2012;43:537-45
- Reyes C, DaCosta Byfield S, Linke R, et al. The burden of metastatic melanoma: treatment patterns, healthcare use (utilization), and costs. Melanoma Res 2013;23:159-66
- National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Melanoma, Version 4.2014. Available at http://www.nccn.org/professionals/physician_gls/pdf/melanoma.pdf [Last accessed 19 May 2014]
- Quan H, Sundararajan V, Halfon P, et al. Coding algorithm for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Medical Care 2005;43:1130-9
- Elixhauser A, Steiner C, Harris DR, Coffey RM. Comorbidity measures for use with administrative data. Med Care 1998;36:8-27
- Jones AM. Health econometrics. In: Culyer A, Newhouse J (eds) Handbook of Health Economics, Vol 1A. North Holland, 2000
- Lin DY. Linear regression analysis of censored medical costs. Biostatistics 2000;1:35-47
- Famoye F, Singh KP. Zero-inflated generalized Poisson regression model with an application to domestic violence data. J Data Sci 2006;4:117-30
- Menzies AM, Haydu LE, Visintin L. Distinguishing clinicopathologic features of patients with V600E and V600K BRAF-mutant metastatic melanoma. Clin Cancer Res 2012;18:3242-9
- Onukwughe E, Yong C, Hussain A, et al. Concordance between administrative claims and registry data for identifying metastasis to the bone: an exploratory analysis in prostate cancer. BMC Med Res Methodol 2014;14:1